Isotype
Whole Humanized Antibody
Description
CDC-enhanced Tildrakizumab is a Fc-modified anti-IL23 therapeutic biobetter. Creative Biolabs' advanced CDC-enhanced antibody platform allows for the production of Fc engineered therapeutic CDC⁺ antibodies. By mutating key amino acids of the Fc region of Tildrakizumab, the Fc region of Tildrakizumab exhibits a greater binding capacity to C1q, thereby achieving enhanced CDC activity.
Indication
Moderate-severe plaque psoriasis
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced Tildrakizumab. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Full Name
interleukin 23 subunit alpha
Background
This gene encodes a subunit of the heterodimeric cytokine interleukin 23 (IL23). IL23 is composed of this protein and the p40 subunit of interleukin 12 (IL12B). The receptor of IL23 is formed by the beta 1 subunit of IL12 (IL12RB1) and an IL23 specific subunit, IL23R. Both IL23 and IL12 can activate the transcription activator STAT4, and stimulate the production of interferon-gamma (IFNG). In contrast to IL12, which acts mainly on naive CD4(+) T cells, IL23 preferentially acts on memory CD4(+) T cells.
Alternative Names
P19; SGRF; IL-23; IL-23A; IL23P19
Groups
Approved, Investigational
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
Humanized IgG1
Description
Tildrakizumab is a humanized IgG1κ antibody designed to treat monoclonal antibodies against immune-mediated inflammatory diseases. The US Food and Drug Administration (FDA) approved Tildrakizumab for the treatment of moderate to severe plaque psoriasis in 2018.
Indication
Moderate-severe plaque psoriasis
Synonyms
tildrakizumab-asmn